Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 8/20 | 0.38 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL840384 | 1.00 | HDAC6 (0.39) | HDAC6P2RX3AVPR1BENPP2HRH3 | |
| SCHEMBL840172 | 0.88 | HRH3 (0.41) | HDAC6ENPP2HRH3HCRTR1HCRTR2 | |
| SCHEMBL840115 | 0.84 | HRH3 (0.41) | HDAC6ENPP2HRH3HCRTR1HCRTR2 | |
| SCHEMBL840087 | 0.83 | NOS1 (0.41) | HDAC6ENPP2HRH3HCRTR1HCRTR2 | |
| SCHEMBL839469 | 0.83 | HRH3 (0.43) | HDAC6ENPP2HRH3HCRTR1HCRTR2 | |
| SCHEMBL840052 | 0.81 | HRH3 (0.41) | HDAC6ENPP2HRH3HCRTR1HCRTR2 | |
| SCHEMBL840327 | 0.80 | ENPP2 (0.51) | ENPP2HRH3HCRTR1HCRTR2 | |
| SCHEMBL839667 | 0.79 | CXCR4 (0.44) | HDAC6ENPP2HRH3 | |
| SCHEMBL839962 | 0.79 | HRH3 (0.41) | HDAC6ENPP2HRH3HCRTR1HCRTR2 | |
| SCHEMBL839122 | 0.78 | JAK1 (0.38) | HDAC6ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143246-B2 | 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives | MSD OSS B.V. (NL) | 2012-03-27 | — | — | US | disclosed |
| EP-2373639-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | N.V. Organon (NL) | 2011-10-12 | — | — | EP | disclosed |
| US-20100144724-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | N.V.ORGANON | 2010-06-10 | — | — | US | disclosed |
| WO-2010063666-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | N.V. ORGANON (NL) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144724-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | OPRD1, CNR1, CNR2 | HDAC6 1380/4885P2RX3 212/4885AVPR1B 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.